Beyond the Session Room: Satellite Symposia and Product Theaters
Watch Industry-Supported Programming from Anywhere
In addition to DDW’s original scientific sessions, there are plenty of industry-supported programming that attendees can enjoy. Satellite Symposia (SS) are educational programs that take place before or after DDW scientific sessions. Some SS may offer CME. Product Theaters (PT) are marketing presentations from our industry supporters. View the schedules below and join us in the DDW Theaters (South Hall, Level 3). Select SS and PT will also be livestreamed for online attendees.
Were you unable to attend Satellite Symposia (SS) and Product Theaters at the 2023 meeting in person? Select presentations were recorded so you can catch up on new GI trends and products by watching them on demand below.
Satellite Symposia are educational programs that take place before or after DDW scientific sessions. Some SS may offer CME. Product Theaters are marketing presentations from our industry supporters.
Satellite Symposia
Product Theaters
Saturday, May 6, 2023
| 6 p.m. | Test Your Ability to Manage Patients With Irritable Bowel Syndrome With Constipation: A Live Case-Based Challenge |
| Supported by: Ardelyx Provided by: Medscape |
|
| 6–7:30 p.m. | |
| Regency AB, Second Floor Hyatt Regency McCormick Place |
|
| In this live, interactive symposium, expert faculty will present realistic cases to provide context for evidence-based approaches for the diagnosis and management of constipation- predominant irritable bowel syndrome (IBS-C). A series of polling questions will gauge the audiences’ ability to make key clinician decisions regarding diagnosis and treatment selection. Responses will be used to guide the discussion around evidence-based approaches for IBS-C management, including pharmacologic and non-pharmacologic management approaches, and shared decision-making. Join the livestream here. |
|
| S1P Receptor Modulation and JAK Selectivity in Ulcerative Colitis – A Wheel of Knowledge Challenge! | |
| Supported by: Pfizer, Inc. Provided by: Vindico Medical Education |
|
| Registration and dinner: 6–6:30 p.m. | |
| Regency CD Hyatt Regency Chicago |
|
| Join us for this CME dinner symposium to learn about the safety and efficacy of current and emerging therapies and optimal positioning of S1P receptor modulators and selective JAK inhibitors in the shifting UC treatment paradigm. The symposium will feature the A Wheel of Knowledge. During this highly interactive gaming segment, you and your team will partner with a faculty member to compete to win the Wheel of Knowledge Challenge! Join the livestream here. |
|
| 6:30 p.m. | New Horizons and Expert Insights on the Management of Recurrent Clostridioides difficile Infection |
| Supported by: Seres Therapeutics, Inc., Aimmune Therapeutics, Ferring Pharmaceuticals Inc. Provided by: Medscape |
|
| 6:30–8 p.m. | |
| Regency CDE, Second Floor Hyatt Regency McCormick Place |
|
| Clostridioides difficile causes a serious infection of the lower GI tract, resulting in significant morbidity and sometimes death. Standard antibiotics used to treat toxin-producing C. difficile do not kill the bacterial spores, which leaves patients susceptible to recurrent infections. Novel microbiome-directed biopharmaceutical products are now approved for the prevention of Clostridioides difficile infection (CDI) recurrence and represent a major paradigm shift in the management of CDI. In this hybrid live CME event, clinician experts will review the clinical data on these important new therapies and how they can be incorporated into clinical practice. The audience will have an opportunity to ask questions of the panel in both the live and virtual setting. Join the livestream here. |
|
| Breaking Borders: Optimizing Care for South Asians With IBD in the Mainland and Beyond | |
| Supported by: Takeda Pharmaceuticals U.S.A., Inc., Janssen Pharmaceutical Companies, Lilly Provided by: Clinical Care Options, LLC This CME/CE-program is in conjunction with South Asian IBD Alliance. |
|
| 6:30 p.m. | |
| Prairie Room, Second Floor Hyatt Regency McCormick Place |
|
| IBD is underrecognized and undertreated despite an increasing prevalence in South Asians. Join us at this live, in-person symposium and learn from the experts about the challenges and cultural barriers to IBD care that affect South Asian patients with IBD worldwide. |
Sunday, May 7, 2023
| 6:45 a.m. | Enhancing Outcomes for Adults and Children With EoE: Improving Diagnosis and Targeting Type 2 Inflammation |
| Supported by: Regeneron Pharmaceuticals, Inc and Sanofi Provided by: Answers in CME |
|
| 6:45 a.m. | |
| Regency Ballroom C, D, E Hyatt Regency McCormick Place |
|
| Join Dr. Gary W. Falk and Dr. Ikuo Hirano for a discussion of the latest clinical data targeting type two cytokines in the treatment of eosiophilic esophagitis in both adults and children, as well as strategies for integrating approved and emerging biologics into current treatment paradigms. Join the livestream here. |
|
| 6 p.m. | An Urgent Need in Ulcerative Colitis: Bowel Urgency as a Target for Assessment and Treatment |
| Supported by: Lilly Provided by: Med Learning Group |
|
| Hyatt Regency McCormick Place Regency AB |
|
| 6 p.m. | |
| Join Drs Marla Dubinsky and Parambir Singh Dulai for an interactive discussion focusing on the epidemiology, pathophysiology, diagnosis, and treatment of ulcerative colitis (UC), and aims to result in clinical improvement in the management of UC through an increased understanding of how UC with bowel urgency affects quality of life and clinical outcomes in patients; and an increased ability to apply the latest clinical data on new and emerging agents, and their impact on bowel urgency, to treatment decision making. | |
| 6:15 p.m. | IBS-C: Evidence-Based and Patient-Centered Management Strategies |
| Supported by: AbbVie, Inc., Ironwood Pharmaceuticals Inc. Provided by: HMP Education, an HMP Global Company |
|
| 6:15 p.m. | |
| Regency Ballroom D Hyatt Regency Chicago |
|
| This complimentary CME/CE event aims to provide invaluable insight into the epidemiology, pathophysiology, diagnosis, and management of Irritable Bowel Syndrome with Constipation (IBS-C). Through interactive lectures, a patient advocate, and Q&A sessions, healthcare professionals will master evidence-based guidance and best practices to elevate their patient care. Join us in person for dinner or virtually on a live-streamed webinar to learn more! | |
| 6:30 p.m. | Identifying and Managing Complications of Acute-on-Chronic Liver Failure: Variceal Bleeding, Respiratory and Renal Disease in Patients with Cirrhosis |
| Supported by: Mallinckrodt Pharmaceuticals Provided by: CiME and Purdue University College of Pharmacy |
|
| 6:30 p.m. (Buffet served at 6 p.m.) | |
| Regency CDE Hyatt Regency McCormick Place |
|
| The gastroenterology team managing patients with chronic liver disease must be vigilant for extrahepatic complications of cirrhosis/ACLF. ACLF confers high risk of multi-organ failure and mortality as a result of portal hypertension and systemic vasodilation. Extrahepatic complications including renal and respiratory failure are a significant factor in increased mortality risk. This program will discuss ACLF prognosis and complications, to identify these issues and treat effectively; minimizing time to differential diagnosis of HRS/AKI; removing diuretics, monitoring volume and SCr dynamics to proactively treat using evidence-based vasopressor options for patients with HRS/AKI. Register now: https://cvent.me/ed1G50 Join the livestream here. |
|
| Navigating the New Treatment Landscape in Inflammatory Bowel Disease | |
| Supported by: AbbVie, Inc. Provided by: Medscape |
|
| 6:30–8 p.m. | |
| Prairie Room, Second Floor Hyatt Regency McCormick Place |
|
| The treatment landscape for inflammatory bowel disease (IBD) is changing rapidly. Novel pharmacologic agents with different and unique mechanisms of action that target specific steps in the IBD disease pathway represent significant advances in the treatment of Crohn’s disease and ulcerative colitis. In this live symposium, IBD clinician experts will discuss and differentiate these new and emerging therapies, provide context for their use in clinical practice, and use patient cases to illustrate evolving concepts in risk stratification and treat-to-target approaches. Faculty will also discuss nuances in treatment selection for complex patients and the latest guidance on therapeutic drug monitoring. Join the livestream here. |
|
| Debating Key Concepts in the Management of Nonalcoholic Steatohepatitis | |
| Supported by: Madrigal Pharmaceuticals Provided by: Medscape |
|
| 6:30–8 p.m. | |
| Jackson Park Hyatt Regency McCormick Place |
|
| Join the livestream here. |
Monday, May 8, 2023
| 6 p.m. | Targeting the Metabolic Mechanisms of NAFLD and NASH: A Fresh Horizon for Improved Outcomes |
| Supported by: Novo Nordisk, Inc. Provided by: Institute for Medical and Nursing Education, Inc. |
|
| 6 p.m. | |
| Regency CDE Hyatt Regency McCormick Place |
|
| Join us for a highly interactive symposium featuring multiple opportunities for audience-expert interaction, including case studies and a question-and-answer session. Learners will hear expert faculty summarize the current state of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH), their relationship with metabolic syndrome and metabolic disorders, and guideline recommendations for management. Next, learners will be given the opportunity to put this information to the test in the “What Would You Do?” segment, where they will be challenged to make clinical decisions for several case questions. The faculty will then review the audience responses and discuss evidence-based practices for treatment decisions. All learners will have the opportunity to participate in exclusive virtual “practice clinics” 3 to 6 months following the symposium. During these small-group sessions that allow direct interaction with expert faculty, learners can discuss changes implemented in their clinics, reflect on successes, and receive advice on overcoming any clinical challenges. Register now. Join the livestream here. |
|
| Taking Fuel From the IBD Fire: Applying New Evidence on Sphingosine-1-Phosphate Receptor Modulation as an Effective Oral Option for Management of Ulcerative Colitis | |
| Supported by: Bristol Myers Squibb Provided by: PVI, PeerView Institute for Medical Education |
|
| 6 p.m. | |
| Prairie Room, Second Floor Hyatt Regency McCormick Place |
|
| This interactive event will offer learners an in-depth look at the complex pathophysiology of IBD, current management paradigms, and challenges in the care of patients with moderately to severely active ulcerative colitis, as well as insight into S1PR modulation as a novel nonbiologic therapeutic option and practical guidance on effectively and safely incorporating this strategy into patient care. Join the livestream here. |
Sunday, May 7, 2023
| 9:30 a.m. | RISE ABOVE RECURRENT C. DIFFICILE INFECTION with REBYOTA |
| 9:30 – 10:15 a.m. | |
| DDW Theater 1 | |
| Supported by: Ferring Pharmaceuticals Inc. | |
| 10:20 a.m. | Optimizing Management of Constipation and Abdominal Symptoms in IBS-C |
| 10:20 – 11:05 a.m. | |
| DDW Theater 2 | |
| Supported by: AbbVie | |
| 10:45 a.m. | Bowel Urgency in Ulcerative Colitis |
| 10:45 – 11:30 a.m. | |
| DDW Theater 1 | |
| Supported by: Lilly USA | |
| 11:35 a.m. | UC Results: Exploring clinical outcomes and long-term safety of a JAK inhibitor |
| 11:35 a.m. – 12:20 p.m. | |
| DDW Theater 2 | |
| Supported by: AbbVie | |
| 12:00 p.m. | Integrating new technology in the management of non-dysplastic Barrett's esophagus patients: A case-based discussion with Dr. John Lipham, Dr. Raman Muthusamy & Dr. Harshit Khara |
| 12:00 – 12:45 p.m. | |
| DDW Theater 1 | |
| Supported by: Castle Biosciences | |
| Join the livestream here. | |
| 12:50 p.m. | Partnering With Patients for the Management of Moderate-to-Severe Ulcerative Colitis Using an Oral Prescription Therapy |
| 12:50 – 1:35 p.m. | |
| DDW Theater 2 | |
| Supported by: Pfizer | |
| 1:15 p.m. | Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH): Impact, Identification, and Management |
| 1:15 – 2:00 p.m. | |
| DDW Theater 1 | |
| Supported by: Intercept Pharmaceuticals Inc. | |
| 2:05 p.m. | NASH – A Chronic and Serious Disease |
| 2:05 – 2:50 p.m. | |
| DDW Theater 2 | |
| Supported by: Novo Nordisk | |
| 2:30 p.m. | A Treatment Option That Can Be Used Before Biologics For Your Moderate UC Patients |
| 2:30 – 3:15 p.m. | |
| DDW Theater 1 | |
| Supported by: Bristol Myers Squibb | |
| Join the livestream here. | |
| 3:20 p.m. | How Race Can Affect the Treatment and Diagnostic Journey in IBD |
| 3:20 – 4:05 p.m. | |
| DDW Theater 2 | |
| Supported by: Takeda Pharmaceuticals U.S.A., Inc. |
Monday, May 8, 2023
| 9:30 a.m. | Discover a Different Mechanism of Action to Treat IBS-C: A Case Based Discussion |
| 9:30 – 10:15 a.m. | |
| DDW Theater 1 | |
| Supported by: Ardelyx | |
| 10:20 a.m. | Case By Case: Exploring a patient case in the treatment of moderate to severe CD |
| 10:20 – 11:05 a.m. | |
| DDW Theater 2 | |
| Supported by: AbbVie | |
| 10:45 a.m. | Advancements in the Evaluation and Treatment of Esophageal Disorders |
| 10:45 – 11:30 a.m. | |
| DDW Theater 1 | |
| Supported by: Medtronic | |
| 11:35 a.m. | Rethink the Cycle: Consider ENTYVIO |
| 11:35 a.m. – 12:20 p.m. | |
| DDW Theater 2 | |
| Supported by: Takeda Pharmaceuticals U.S.A., Inc. | |
| 12:00 p.m. | The Importance of Long-Term Clinical Outcomes in Bio-Naive Patients |
| 12:00 – 12:45 p.m. | |
| DDW Theater 1 | |
| Supporter by: Janssen Biotech, Inc. | |
| 12:50 p.m. | Eosinophilic Esophagitis: Discover a Treatment Option for Your Patients |
| 12:50 – 1:35 p.m. | |
| DDW Theater 2 | |
| Supported by: Sanofi and Regeneron | |
| 1:15 p.m. | Breaking the cycle of recurrence: New preventative treatment option for recurrent C. difficile infection |
| 1:15 – 2:00 p.m. | |
| DDW Theater 1 | |
| Supported by: Nestlé Health Science I Seres Therapeutics, Inc. | |
| 2:05 p.m. | Exciting development in the treatment of Hepatorenal Syndrome |
| 2:05 – 2:50 p.m. | |
| DDW Theater 2 | |
| Supported by: Mallinckrodt Pharmaceuticals | |
| 2:30 p.m. | Overview of Chronic Idiopathic Constipation: Focus On Treatment and New Technology |
| 2:30 – 3:15 p.m. | |
| DDW Theater 1 | |
| Supported by: Vibrant Gastro | |
| 3:20 p.m. | Optimizing Patient Outcomes in GERD with TIF 2.0 |
| 3:20 – 4:05 p.m. | |
| DDW Theater 2 | |
| Supported by: EndoGastric Solutions |
Tuesday, May 9, 2023
| 9:30 a.m. | Optimizing the Treatment Pathway for Patients with PBC: A Case-Based Discussion |
| 9:30 – 10:15 a.m. | |
| DDW Theater 1 | |
| Supported by: Intercept Pharmaceuticals Inc. | |
| 10:20 a.m. | A Proactive Way to Treat IBS-D: Post-Marketing Information and Phase 4 Data |
| 10:20 – 11:05 a.m. | |
| DDW Theater 2 | |
| Supported by: AbbVie | |
| 10:45 a.m. | GI PCR Panels: How to Utilize Molecular Syndromic Testing in Your Practice |
| 10:45 – 11:30 a.m. | |
| DDW Theater 1 | |
| Supported by: bioMérieux, Inc. | |
| 12:50 p.m. | Treatment Options for Certain Patients With Select Advanced Upper Gastrointestinal Cancers |
| 12:50 – 1:35 p.m. | |
| DDW Theater 2 | |
| Supported by: Merck | |
| 1:15 p.m. | Eosinophilic Esophagitis: Clinical Implications of Disease Progression |
| 1:15 – 2:00 p.m. | |
| DDW Theater 1 | |
| Supported by: Sanofi and Regeneron |
You May Be Interested in...
CME Credit & Certificate of Attendance
The DDW 2023 CME Claim site will be open May 6–Oct. 31, 2023. The same link will be used to generate a Certificate of Attendance.
Source the Latest Innovations
Discover the latest GI innovations in the Exhibit Hall and online Industry Supporter Directory.
